Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist

Advancing the Field of Pharmaceutical Risk Minimization Through Application of Implementation Science Best Practices

(2014) Meredith Y. Smith et al.   DRUG SAFETY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

(2013) Kenneth F. Schulz   ANNALS OF INTERNAL MEDICINE

The Promise of Pharmacoepidemiology in Helping Clinicians Assess Drug Risk

(2013) Jerry Avorn   CIRCULATION

When Direct Health-Care Professional Communications Have an Impact on Inappropriate and Unsafe Use of Medicines

(2013) K C Reber et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

If You Don’t Know Where You Are Going, You Can’t Tell If You Have Arrived: Defining Goals for Drug Safety Announcements

(2013) A J J Wood   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Globalization of Risk and Risk Perception

(2013) Heidi Larson et al.   DRUG SAFETY

Challenges of Drug Risk Communications in the Philippines

(2013) Kenneth Hartigan-Go   DRUG SAFETY

Good Decision Making Requires Good Communication

(2013) Baruch Fischhoff   DRUG SAFETY

Risk Perception and Communication in Sub-Saharan Africa

(2013) Alexander Dodoo et al.   DRUG SAFETY

Reporting of Noninferiority and Equivalence Randomized Trials

(2013) Gilda Piaggio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reporting of Patient-Reported Outcomes in Randomized Trials

(2013) Melanie Calvert et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

(2013) Don Husereau et al.   VALUE IN HEALTH

Impact of Safety-Related Regulatory Action on Drug Use in Ambulatory Care in the Netherlands

(2012) S Piening et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

(2012) Stacie B. Dusetzina et al.   MEDICAL CARE

Consort 2010 statement: extension to cluster randomised trials

(2012) M. K. Campbell et al.   BMJ-British Medical Journal

Application of the BRAT Framework to Case Studies: Observations and Insights

(2010) B S Levitan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines

(2010) P M Coplan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Decade of Safety-Related Regulatory Action in the Netherlands

(2010) Peter G.M. Mol et al.   DRUG SAFETY

Public Pharmacovigilance Communication

(2010) Priya Bahri   DRUG SAFETY

AHRQ Series Paper 5: Grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health-Care Program

(2009) Douglas K. Owens et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Safety profile of Tysabri: international risk management plan

(2009) P. Iaffaldano et al.   NEUROLOGICAL SCIENCES